5,421
edits
Glycoprotein IIb/IIIa inhibitors: Difference between revisions
no edit summary
(Created page with "'''Glycoprotein IIb/IIIa inhibitors''' are antiplatelets. They are mostly used for short-term treatment before and during percutaneous coronary intervention. They are administered by i.v. injection, == Compounds == * Abciximab * Eptifibatide * Tirofiban == Mechanism of action == These drugs bind to and inhibit the receptors glycoprotein IIb/IIIa, which prevents platelets from binding to each other and therefore preventing aggregation.<noinclude>Category:Pharmaco...") |
No edit summary |
||
| Line 1: | Line 1: | ||
'''Glycoprotein IIb/IIIa inhibitors''' are antiplatelets. They are mostly used for short-term treatment before and during [[percutaneous coronary intervention]]. They are administered by i.v. injection, | '''Glycoprotein IIb/IIIa inhibitors''' are [[Antiplatelet drugs|antiplatelets]]. They are mostly used for short-term treatment before and during [[percutaneous coronary intervention]]. They are administered by i.v. injection, | ||
== Compounds == | == Compounds == | ||
| Line 8: | Line 8: | ||
== Mechanism of action == | == Mechanism of action == | ||
These drugs bind to and inhibit the receptors glycoprotein IIb/IIIa, which prevents platelets from binding to each other and therefore preventing aggregation.<noinclude>[[Category:Pharmacology]]</noinclude> | These drugs bind to and inhibit the receptors glycoprotein IIb/IIIa, which prevents platelets from binding to each other and therefore preventing aggregation.<noinclude> | ||
[[Category:Pharmacology]] | |||
</noinclude> | |||